VYGR — Voyager Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $414.44m
- $183.56m
- $250.01m
- 69
- 94
- 90
- 97
Annual cashflow statement for Voyager Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -43.6 | 36.7 | -71.2 | -46.4 | 132 |
| Depreciation | |||||
| Non-Cash Items | 11.1 | 7.26 | 9.21 | 7.24 | 7.71 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 78.4 | -145 | 3.29 | 20.5 | -66.6 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | 48.7 | -96.7 | -53.5 | -12.5 | 77.9 |
| Capital Expenditures | -7.72 | -12.1 | -1.61 | -2.49 | -3.26 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -82.8 | 125 | 67.5 | -4.85 | -138 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -90.5 | 113 | 65.9 | -7.34 | -142 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 81 | 3.16 | 0.612 | 1.11 | 33.6 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 39.2 | 19.4 | 13 | -18.7 | -30.1 |